Skip to main content
SpringerLink
Log in

NASH – eine ungelöste therapeutische Herausforderung

Aktuelle Therapiekonzepte

NASH – an unresolved therapeutic challenge

Current therapy concepts

  • Schwerpunkt
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Als Erkrankungen, die pathogenetisch eng mit dem metabolischen Syndrom in Zusammenhang stehen, sind NAFLD und NASH in der westlichen Zivilisation eine der häufigsten Ursachen chronischer Lebererkrankungen. Vor dem Hintergrund einer immer weiter zunehmenden Prävalenz von Adipositas und Diabetes mellitus Typ 2 kommen Therapiekonzepten für diese Hepatopathien große Bedeutung zu. Eine besondere Herausforderung stellt die NASH bei Patienten ohne typische Konstellation des metabolischen Syndroms dar. In diesem Beitrag werden die bislang vorliegenden Daten zur gezielten Behandlung der NASH zusammenfasst.

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are closely associated with the metabolic syndrome and are regarded as very important conditions leading to chronic liver disease in western countries. Considering the constantly increasing incidence in obesity and type 2 diabetes mellitus, new therapeutic concepts especially in the treatment of NASH are urgently needed. Patients with NASH lacking characteristic features of the metabolic syndrome are particularly challenging in this context. In this review an overview of currently available data is provided that should be considered in the care of patients with NASH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abid A, Taha O, Nseir W et al (2009) Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 51: 918–924

    Article  CAS  PubMed  Google Scholar 

  2. Adams LA, Zeine CO, Angulo P et al (2004) A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99: 2365–2368

    Article  CAS  PubMed  Google Scholar 

  3. Aithal GP, Thomas JA, Kaye PV et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176–1184

    Article  CAS  PubMed  Google Scholar 

  4. Ali R, Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41: 265–278

    Article  CAS  PubMed  Google Scholar 

  5. Angelico F, Burattin M, Alessandri C et al (2007) Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev CD005166

  6. Angelico F, Del Ben M, Conti R et al (2005) Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90: 1578–1582

    Article  CAS  PubMed  Google Scholar 

  7. Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356–1362

    Article  CAS  PubMed  Google Scholar 

  8. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297–2307

    Article  CAS  PubMed  Google Scholar 

  9. Browning JD, Davis J, Saboorian MH, Burgess SC (2006) A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. Hepatology 44: 487–488

    Article  PubMed  Google Scholar 

  10. Bugianesi E, Gentilcore E, Manini R et al (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082–1090

    Article  CAS  PubMed  Google Scholar 

  11. Campbell JM, Hunt TK, Karam JH, Forsham PH (1977) Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 137: 602–610

    Article  CAS  PubMed  Google Scholar 

  12. De Luis DA, Aller R, Izaola O et al (2008) Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance. Diabetes Res Clin Pract 79: 74–78

    Article  Google Scholar 

  13. Furuya CK, Olivereira CP de, Mello ES de et al (2007) Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 22: 510–514

    Article  CAS  PubMed  Google Scholar 

  14. Harrison SA, Day CP (2007) Benefits of lifestyle modification in NAFLD. Gut 20: 29–43

    Google Scholar 

  15. Harrison SA, Fincke C, Helinski D et al (2004) A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20: 623–628

    Article  CAS  PubMed  Google Scholar 

  16. Harrison SA, Torgerson S, Hayashi P et al (2003) Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2485–2490

    Article  CAS  PubMed  Google Scholar 

  17. Johnson NA, Sachinwalla T, Walton DW et al (2009) Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50: 1105–1112

    Article  CAS  PubMed  Google Scholar 

  18. Lam BP, Younossi ZM (2009) Treatment regimes for non-alcoholic fatty liver disease. Ann Hepatol 8: S51–S59

    PubMed  Google Scholar 

  19. Liu X, Lazenby AJ, Clements RH et al (2007) Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 17: 486–492

    Article  PubMed  Google Scholar 

  20. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923

    Article  PubMed  Google Scholar 

  21. Marubbio AT, Buchwald H, Schwartz MZ et al (1976) Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoilealbypass. Am J Clin Pathol 66: 684–691

    PubMed  Google Scholar 

  22. Mathurin P, Hollebecque A, Arnalsteen L et al (2009) Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterol 137: 532–540

    Article  CAS  Google Scholar 

  23. Mattar SG, Velcu LM, Rabinovitz M et al (2005) Surgically-induced weight loss significantly improved nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242: 610–620

    PubMed  Google Scholar 

  24. Musso G, Gambino R, De Michieli F et al (2003) Dietary habits and their relations to insulin resistance and post-prandial lipemia in nonalcoholic steatohepatitis. Hepatology 37: 909–913

    Article  CAS  PubMed  Google Scholar 

  25. Okita M, Hayashi M, Sasagawa T et al (2001) Effect of moderately energy-restricted diet on obese patients with fatty liver. Nutrition 17: 542–547

    Article  CAS  PubMed  Google Scholar 

  26. Patel AA, Torres DM, Harrison SA et al (2009) Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol 43: 970–974

    Article  PubMed  Google Scholar 

  27. Promrat K, Kleiner DE, Niemeier HM et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51: 121–129

    CAS  PubMed  Google Scholar 

  28. Ratziu V, Charlotte F, Bernhardt C et al (2009) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology 51: 445–453

    Google Scholar 

  29. Ratziu V, Giral P, Jaqueminet S et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. Gastroenterol 135: 100–110

    Article  CAS  Google Scholar 

  30. Ryan MC, Abbasi F, Lamendola C et al (2007) Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 30: 1075–1080

    Article  CAS  PubMed  Google Scholar 

  31. Satapathy SK, Sakhuja P, Malhotra V et al (2006) Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22: 634–638

    Google Scholar 

  32. Sato F, Tamura Y, Watada H et al (2006) Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 92: 3326–3329

    Google Scholar 

  33. Tendler D, Lin S, Yancy WS Jr et al (2007) The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 52: 589–593

    Article  CAS  PubMed  Google Scholar 

  34. Torres DM, Harrison SA (2008) Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterol 134: 1682–1698

    Article  CAS  Google Scholar 

  35. Uygun A, Kadayifci A, Isik AT et al (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19: 537–544

    Article  CAS  PubMed  Google Scholar 

  36. Valenti L, Fracanzani AL, Dongiovanni P et al (2007) Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 102: 1251–1258

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Universitätsklinik, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland

    U. Schempf, U.M. Lauer, M. Gregor &  M. Bitzer

Authors
  1. U. Schempf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U.M. Lauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Bitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bitzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schempf, U., Lauer, U., Gregor, M. et al. NASH – eine ungelöste therapeutische Herausforderung. Gastroenterologe 5, 123–128 (2010). https://doi.org/10.1007/s11377-009-0370-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-009-0370-7

Schlüsselwörter

Keywords

Search

Navigation